 ROCKVILLE, MD, Jan. 04, 2023 GLOBE NEWSWIRE MacroGenics, Inc. Nasdaq: MGNX, a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the company will participate in the 41st Annual J.P. Morgan Healthcare Conference. Scott Koenig, M.D., Ph.D., President Chief Executive Officer of MacroGenics, ... The post MacroGenics to Present at the 41st Annual J.P. Morgan Healthcare Conference appear... 